Search This Blog

Thursday, February 28, 2019

Reata Pharmaceuticals reports Q4 EPS (86c), consensus ($1.07)

Reports Q4 revenue $8.45M, may not compare to consensus $6.06M. “At December 31, 2018, we had $337.8 million in cash and cash equivalents. We expect our current cash to fund our operations through data readouts for our three ongoing registrational clinical trials.”

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.